Breaking News

MethylGene Makes Management Changes

March 15, 2013

Besterman, Baum and Gergen assume new roles

Jeffrey M. Besterman, Ph.D., has been appointed executive vice president of R&D and chief scientific officer at MethylGene, Inc. Joe Walewicz, vice president of business and corporate development, and Klaus B. Kepper, vice president finance and chief financial officer, will be leaving the company.
 
Dr. Charles Baum, chief executive officer, will take over Dr. Besterman’s responsibilities and Mark Gergen, chief operating officer has assumed the responsibilities of Mr. Kepper and Mr. Walewicz. 
 
"I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene," said Dr. Baum. “We wish them the best in their future pursuits.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision